Home

Anne Clem Whitaker

CIK 1593283 · Director · last filed 2026-08-12

Anne Clem Whitaker is a Director who has filed 36 SEC Form 4 insider transactions across 6 companies since 2013. The most recent filing, for ICLR, was dated Aug 12, 2026. Across all open-market trades the lifetime net is −$2.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $249.0K across reported positions. 8 SEC filings were submitted jointly with Bausch Health Companies Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$249.0K

Companies

6

Total Filings

36

Lifetime Open-Market Net

-$2.22M

Filer Profile

Reported Address
109 BRIERY BRANCH COURT
MORRISVILLE, NC 27560
Related Filers
Bausch Health Companies Inc. — 8 joint filings, latest 2016-12-20
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ICLR Director 958 $164.85 $157.9K -$138.2K 1 2026-08-12
OSUR Director 26,163 $3.48 $91.0K $0 3 2023-05-17
LISATA THERAPEUTICS, INC. (CLBS) Delisted Director 12,176 $6.40 $77.9K $0 3 2022-01-12
Keenova Therapeutics plc (MNK) Delisted Director 0 $0.34 $0 -$2.7K 4 2020-11-10
WOLFSPEED, INC. (CREE) Delisted Director 11,274 $79.12 $892.0K -$2.08M 15 2020-11-06
MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted President and CEO 500,000 — — $0 2 2015-03-04

Recent Filings

36 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-12 ICLR Mixed +891 -$138.2K EDGAR
2026-08-11 ICLR Notice (144) −841 -$138.2K EDGAR
2023-05-17 OSUR Tax (F) −6,723 -$37.0K EDGAR
2022-05-18 OSUR Grant (A) +20,000 $105.0K EDGAR
2022-01-12 LISATA THERAPEUTICS, INC. (CLBS) Delisted Grant (A) +65,430 $0 EDGAR
2021-11-10 OSUR Grant (A) +10,563 $105.0K EDGAR
2021-01-12 LISATA THERAPEUTICS, INC. (CLBS) Delisted Grant (A) +37,735 $0 EDGAR
2020-11-10 Keenova Therapeutics plc (MNK) Delisted Sell (S) −21,087 -$2.7K EDGAR
2020-11-06 WOLFSPEED, INC. (CREE) Delisted Mixed −25,248 -$1.76M EDGAR
2020-11-03 LISATA THERAPEUTICS, INC. (CLBS) Delisted Grant (A) +79,470 $120.0K EDGAR
Showing 1–10 of 36
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.